Ekdv-691 Jun 2026

| Study | Model | Dose / Regimen | Key Findings | |-------|-------|----------------|--------------| | | Human primary lung fibroblasts (TGF‑β1‑stimulated) | 0.1–100 nM | Dose‑dependent ↓ α‑SMA, collagen‑I, fibronectin; EC₅₀ ≈ 15 nM | | DDR1‑dependent migration | Collagen‑I coated Boyden chamber with DDR1‑expressing CAFs | 10–500 nM | 80 % inhibition of migration at 100 nM | | Bleomycin‑induced lung fibrosis (C57BL/6 mice) | 10 mg/kg PO q.d. (14 d) starting day 7 post‑bleomycin | ↓ hydroxyproline content by 62 %; histology: ↓ Ashcroft score (3.1 → 1.1) | | Unilateral ureteral obstruction (UUO) renal fibrosis (rats) | 30 mg/kg PO q.d. (21 d) | ↓ renal collagen deposition by 48 % and preserved GFR | | Patient‑derived xenograft (PDX) of desmoplastic pancreatic cancer | 30 mg/kg PO q.d. + gemcitabine | Tumour volume reduction 55 % vs. gemcitabine alone; stromal α‑SMA density ↓ 70 % | | Safety pharmacology | hERG assay, CNS battery, cardiovascular telemetry in dogs | No QTc prolongation at 30× human Cmax; no CNS behavioural changes | | GLP toxicology | 4‑week repeat dose in rat & dog | NOAEL: 100 mg/kg (rat), 60 mg/kg (dog). No target‑organ toxicity, no mutagenicity (Ames, mouse micronucleus). |

[ EK ] [ DV ] - [ 691 ] Prefix Block Class Modifier Numeric Sequence EKDV-691

Regulatory bodies and domain tracking authorities frequently deploy alphanumeric tags to categorize active registrations and asset inventories. | Study | Model | Dose / Regimen

[System Operational] ──> [Real-time Sensor Monitoring] ──> [Slight Deviation Detected] │ [System Restored] <── [Component Calibration / Seal Swapping] <───┘ Scheduled Visual Audits + gemcitabine | Tumour volume reduction 55 % vs

In modern process engineering, EKDV denotes an integrated with automated digital controllers. These assemblies are critical components in Safety Instrumented Systems (SIS), engineered to isolate flows instantly when critical limits are breached.